ArticleVirchows Archiv : an international journal of pathology2025
SOX11 is frequently expressed in ETV6::NTRK3-rearranged infantile fibrosarcoma and congenital mesoblastic nephroma.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Not all NTRK fusions in mesenchymal neoplasia are driver events: implications on classification and targeted therapy.The journal of pathology. Clinical research · 2026Article
- Sclerosing perineurioma of the anterior chest wall in an active Caucasian toddler: a case report.Translational pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Definitive diagnosis of infantile fibrosarcoma (IFS) and related kinase-altered spindle cell neoplasms (SCN) requires immunohistochemistry (IHC) or molecular assays that are variable in performance or not widely available. Recent transcriptomic studies identified differential gene expression in IFS with ETV6::NTRK3 fusions, prompting investigation of SOX11 expression pattern by IHC in IFS/IFS-like SCN and morphologic mimics. SOX11 staining (MRQ-58) was performed on 201 spindle cell tumors, including 28 IFS and congenital mesoblastic nephroma (CMN) with ETV6::NTRK3 fusion, 44 IFS/IFS-like SCN with alternative kinase fusions, 15 inflammatory myofibroblastic tumor, 4 dermatofibrosarcoma protuberans, 6 myofibroma, and 104 mimics comprising 38 malignant peripheral nerve sheath tumor (MPNST), 24 synovial sarcoma, 19 desmoid fibromatosis, 7 neurofibroma, 4 schwannoma, 4 fibrous hamartoma of infancy, 4 spindle cell/sclerosing rhabdomyosarcoma (SRMS), and 4 clear cell sarcoma of kidney (CCSK). SOX11 was positive in 18/28 (64%) ETV6::NTRK3-rearranged IFS/CMN (21% with diffuse strong nuclear expression and 43% with multifocal moderate to strong positivity) and 3/69 (4%) other kinase-altered tumors, including one EGFR-altered tumor and two cellular myofibromas. SOX11 was positive in 5/24 (21%) synovial sarcoma, 6/38 (16%) MPNST, 2/4 (50%) SRMS, and all 4 CCSK. Overall, SOX11 was 64% sensitive for ETV6::NTRK3-fused IFS/CMN and 96% specific compared to kinase-altered tumors, with 88% specificity compared to all mimics. SOX11 is moderately sensitive but highly specific for IFS/CMN with ETV6::NTRK3 fusion. In the correct context, SOX11 shows utility as a screening adjunct for focused molecular testing.
Indexed as
Identifiers
41175194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.